What You Need To Know About The MedinCell S.A. (EPA:MEDCL) Analyst Downgrade Today
The latest analyst coverage could presage a bad day for MedinCell S.A. (EPA:MEDCL), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.
Following the downgrade, the current consensus from MedinCell's six analysts is for revenues of €39m in 2027 which - if met - would reflect a sizeable 60% increase on its sales over the past 12 months. Before the latest update, the analysts were foreseeing €44m of revenue in 2027. It looks like forecasts have become a fair bit less optimistic on MedinCell, given the substantial drop in revenue estimates.
See our latest analysis for MedinCell
There was no particular change to the consensus price target of €35.51, with MedinCell's latest outlook seemingly not enough to result in a change of valuation.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's clear from the latest estimates that MedinCell's rate of growth is expected to accelerate meaningfully, with the forecast 60% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 28% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 4.4% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect MedinCell to grow faster than the wider industry.
The Bottom Line
The clear low-light was that analysts slashing their revenue forecasts for MedinCell this year. Analysts also expect revenues to grow faster than the wider market. Overall, given the drastic downgrade to this year's forecasts, we'd be feeling a little more wary of MedinCell going forwards.
Of course, this isn't the full story. We have estimates for MedinCell from its six analysts out until 2029, and you can see them free on our platform here.
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.